logo
TakedaPresentsOrexinDatafromLandmarkOveporexton(TAK-861)Phase3PrograminNarcolepsyType1atWorldSleep2025
===2025/9/8 15:01:51===
structure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at:https://www.takeda.com/investors/sec-filings-and-security-reports/or atwww.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for diffe
=*=*=*=*=*=
当前为第16/18页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页